Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02836522 · ClinicalTrials.gov registry record
Validation of a Health-Related Symptom Index for Persons Diagnosed With and Either Treated or Monitored for Anal High-Grade Squamous Intraepithelial Lesions (HSIL)
A clinical trial, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- 406
- Enrollment target
NCT02836522: Completed study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT02836522 is a clinical trial that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 406 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02836522 has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- 406 participants
- Enrollment target
Study Summary
The purpose of this study is to finalize development of a questionnaire that measures health-related symptoms and concerns for persons diagnosed with, and either treated or monitored for, anal pre-cancer lesions.
Primary Outcome
measure from the initial assessment point to the 7-10 day follow-up.
Interventions
- BEHAVIORAL Assessment of Health-Related Quality
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 406 participants |
| Start Date | 2016-04-25 |
| Est. Completion | 2023-08-31 |
What the finished NCT02836522 record still lists
NCT02836522 is an observational study that tracks outcomes without assigning an intervention. The registered 406 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Assessment of Health-Related Quality is the first listed.
NCT02836522 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02836522 about?
NCT02836522 is a clinical study titled "Validation of a Health-Related Symptom Index for Persons Diagnosed With and Either Treated or Monitored for Anal High-Grade Squamous Intraepithelial Lesions (HSIL)". The purpose of this study is to finalize development of a questionnaire that measures health-related symptoms and concerns for persons diagnosed with, and either treated or monitored for, anal pre-cancer lesions.
What is the current status of trial NCT02836522?
This trial is currently completed. The enrollment target is 406 participants. The study started on 2016-04-25. Estimated completion is 2023-08-31.
What interventions are being tested in trial NCT02836522?
The interventions under investigation include: Assessment of Health-Related Quality (BEHAVIORAL).
Who is sponsoring clinical trial NCT02836522?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06223360 · 406 participants · Phase 2
A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)
- NCT06411769 · 406 participants · NA
Evidence-based Intervention to Improve Walking Engagement in El Paso, Texas
- NCT06585787 · 406 participants · Phase 3
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
- NCT06735534 · 407 participants · NA
Repeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI